Journal article
Impact of rarity on Canadian oncology health technology assessment and funding
Abstract
OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) evaluates new cancer drugs for public funding recommendations. While pCODR's deliberative framework evaluates overall clinical benefit and includes considerations for exceptional circumstances, rarity of indication is not explicitly addressed. Given the high unmet need that typically accompanies these indications, we explored the impact of rarity on oncology HTA recommendations and …
Authors
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A
Journal
International Journal of Technology Assessment in Health Care, Vol. 36, No. 4, pp. 404–409
Publisher
Cambridge University Press (CUP)
Publication Date
August 2020
DOI
10.1017/s0266462320000483
ISSN
0266-4623